



## **Pulmonx to Report First Quarter 2022 Financial Results on May 3, 2022**

April 19, 2022

REDWOOD CITY, Calif., April 19, 2022 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) ("Pulmonx"), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the first quarter of 2022 after the close of trading on Tuesday, May 3, 2022. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET.

Investors interested in listening to the conference call may do so by dialing (833) 614-1518 for domestic callers or (270) 823-1072 for international callers, followed by Conference ID: 2575271. A live and archived webcast of the event will be available on the "Investors" section of the Pulmonx website at <https://investors.pulmonx.com/>.

### **About Pulmonx Corporation**

Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for severe lung disease. Pulmonx's Zephyr<sup>®</sup> Endobronchial Valve, Chartis<sup>®</sup> Pulmonary Assessment System and StratX<sup>®</sup> Lung Analysis Platform are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a "breakthrough device." The Zephyr Valve is commercially available in more than 25 countries, with over 100,000 valves used to treat more than 25,000 patients. For more information on the Zephyr Valves, please visit <https://uspatients.pulmonx.com/>. For more information on the company, please visit [www.Pulmonx.com](http://www.Pulmonx.com).

Pulmonx<sup>®</sup>, Chartis<sup>®</sup>, StratX<sup>®</sup>, and Zephyr<sup>®</sup> are registered trademarks of Pulmonx Corporation.

### **Contact**

Brian Johnston  
Gilmartin Group  
[investors@pulmonx.com](mailto:investors@pulmonx.com)